Grade 3 pneumonitis has been reported in 0.6% and 2% of patients with advanced NSCLC in the BIRCH (Study of Atezolizumab in Participants With PD-L1 Positive Locally Advanced or Metastatic Non–Small-Cell Lung Cancer) [63] and POPLAR (Study of Atezolizumab versus docetaxel for patients with previously treated NSCLC) studies [64], respectively. This evidence concerns the gene CD274 and pneumonitis.